6-(Quinolin-5-yl)-4-(4-(vinylsulfonyl)piperazin-1-yl)-thieno[2,3-d]pyrimidine

ID: ALA4878266

PubChem CID: 164628569

Max Phase: Preclinical

Molecular Formula: C21H19N5O2S2

Molecular Weight: 437.55

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C=CS(=O)(=O)N1CCN(c2ncnc3sc(-c4cccc5ncccc45)cc23)CC1

Standard InChI:  InChI=1S/C21H19N5O2S2/c1-2-30(27,28)26-11-9-25(10-12-26)20-17-13-19(29-21(17)24-14-23-20)16-5-3-7-18-15(16)6-4-8-22-18/h2-8,13-14H,1,9-12H2

Standard InChI Key:  BVWONCJVXRZIPH-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 30 34  0  0  0  0  0  0  0  0999 V2000
   11.2426   -2.0884    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.0639   -2.0884    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   11.6512   -1.3765    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.0639   -2.9097    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3581   -3.3224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3581   -4.1437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0675   -4.5523    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.7769   -4.1437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7769   -3.3224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0675   -5.3728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3536   -5.7808    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3536   -6.6014    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0657   -7.0149    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.7767   -6.5956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7767   -5.7786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5522   -5.5219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0347   -6.1802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5616   -6.8413    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   14.8529   -6.1802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2701   -6.8866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0907   -6.8866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4950   -6.1658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7794   -1.6757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7794   -0.8543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2578   -5.4546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0767   -5.4585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4878   -4.7524    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.0810   -4.0419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2590   -4.0419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8516   -4.7486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  2  1  0
  5  4  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9  4  1  0
  7 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 15 14  2  0
 15 10  1  0
 16 15  1  0
 17 16  2  0
 18 17  1  0
 14 18  1  0
 17 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 26  1  0
 25 19  1  0
  2 23  1  0
 23 24  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 25  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA4878266

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 437.55

Molecular Weight (Monoisotopic): 437.0980

AlogP: 3.50

#Rotatable Bonds: 4

Polar Surface Area: 79.29

Molecular Species: NEUTRAL

HBA: 7

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 4.41

CX LogP: 3.10

CX LogD: 3.10

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.49

Np Likeness Score: -1.61

References

1. Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L..  (2021)  Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer.,  64  (16.0): [PMID:34351741] [10.1021/acs.jmedchem.1c00678]

Source

Source(1):

• Scientific Literature